Nearly one-third of patients who responded to a survey did not understand common skin cancer terms frequently used by ...
Backers of the ASX-listed pathology player are pushing for a break-up of the company as new boss Jim Newcombe reviews the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback